Navigation Links
Augmenix, Inc. Closes $6.1 Million Financing

WALTHAM, Mass., Oct. 16 /PRNewswire/ -- Augmenix announced today that it has closed a $6.1 million Series B financing. The round was led by Ascension Health Ventures (AHV) in St. Louis, Mo., with continued participation by existing investors, Versant Ventures and Pinnacle Ventures. Also participating were Catalyst Health Ventures and several private investors.

"The field of radiation oncology has traditionally been of a large capital equipment mindset in solving problems. Augmenix plans to bring novel biomaterials technology into this field to create absorbable devices that will have a huge impact on how clinicians are able to improve targeting of radiotherapy while minimizing radiation damage to organs at risk," commented Amar Sawhney, Augmenix President and CEO.

The proceeds will be used to conduct the clinical and commercial development of the SpaceOAR((TM)). System in Europe and the United States, as well as to develop other products in the Augmenix pipeline.

"We are excited about working with Augmenix to meet significant medical needs in radiation oncology and urology. We have worked with Amar and his team before and like the technology, as well as the rapid and cost-effective execution model embraced by Augmenix," said Tara Butler, Investment Director, AHV, who will join the company's Board of Directors.

About Augmenix, Inc.:

Augmenix, Inc. is a privately held company based in Waltham, Mass., focused on the development and commercialization of implantable biomaterial based solutions for improved radiotherapy safety and/or efficacy. Augmenix's first product, SpaceOAR system is an injectable tissue spacer that will decrease rectal morbidity or enable improved efficacy in prostate radiotherapy. The company was founded in 2008.

About Ascension Health Ventures:

Ascension Health Ventures ( was launched in 2001 as a wholly-owned subsidiary of Ascension Health. AHV's role has been to construct and manage a strategic portfolio of investments that deliver a venture investment return, have the potential to transform the healthcare industry and significantly enhance the quality of patient care. CHV II, LP, a limited partnership between Ascension Health, Catholic Health Initiatives, Catholic Health East and Catholic Healthcare West, has been formed to expand this strategic investment initiative to other Catholic healthcare systems. AHV is the general partner of CHV II, LP.

SOURCE Augmenix, Inc.

SOURCE Augmenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Beckman Coulter Announces Third Quarter 2009 Earnings to be Released on Thursday, October 29, 2009, After Market Closes
2. Archi-Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull-Through Reporting Capabilities
3. Greenway Medical Technologies Closes 11th Consecutive Fiscal Year of Positive Growth
4. AdvanDx Closes $8 Million Financing Round and Elects New Board Member
5. HeartWare International, Inc. Closes US$60 Million Financing
6. Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days
7. Croff Enterprises, Inc. Closes Merger and Will Change Name to Americas Minority Health Network, Inc.
8. Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales
9. Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery
10. Providence Service Corporation to Report Second Quarter 2009 Results on Monday, August 10th After the Market Closes
11. SecureWorks Closes Acquisition of VeriSigns Managed Security Services Business
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology: